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Abstract. 
 
The Chediak-Higashi syndrome (CHS) is a 
human recessive autosomal disease caused by muta-
tions in a single gene encoding a protein of unknown 
function, called lysosomal-trafficking regulator. All 
cells in CHS patients bear enlarged lysosomes. In addi-
tion, T- and natural killer cell cytotoxicity is defective in 
these patients, causing severe immunodeficiencies. We 
have analyzed major histocompatibility complex class 
II functions and intracellular transport in Epstein Barr 
Virus–transformed B cells from CHS patients. Peptide 
loading onto major histocompatibility complex class II 
molecules and antigen presentation are strongly de-
layed these cells. A detailed electron microscopy analy-
sis of endocytic compartments revealed that only lyso-
somal multilaminar compartments are enlarged 
(reaching 1–2 
 
m
 
m), whereas late multivesicular endo-
somes have normal size and morphology. In contrast to 
giant multilaminar compartments that bear most of the 
usual lysosomal markers in these cells (HLA-DR, 
HLA-DM, Lamp-1, CD63, etc.), multivesicular late 
endosomes displayed reduced levels of all these mole-
cules, suggesting a defect in transport from the 
 
trans
 
-
Golgi network and/or early endosomes into late multi-
vesicular endosomes. Further insight into a possible 
mechanism of this transport defect came from immu-
nolocalizing the lysosomal trafficking regulator protein, 
as antibodies directed to a peptide from its COOH ter-
minal domain decorated punctated structures partially 
aligned along microtubules. These results suggest that 
the product of the
 
 Lyst
 
 gene is required for sorting en-
dosomal resident proteins into late multivesicular en-
dosomes by a mechanism involving microtubules.
 
M
 
ajor
 
 histocompatibility complex (MHC)
 
1
 
 class II
molecules are composed of an 
 
ab
 
 dimer that as-
sociates in the ER with a third membrane mole-
cule, the invariant chain (Ii; 33, 24). The 
 
ab
 
-
 
Ii chain com-
plexes are transported via the Golgi apparatus to the
endocytic pathway, directed by a signal localized in the cy-
toplasmic tail of Ii chain (7, 41). Ii chain is then degraded
(12), and upon complete removal of the remaining Ii frag-
ments (60), antigenic peptides are loaded onto class II
molecules under the control of HLA-DM (65, 22).
Ii chain cleavage and antigen processing to fitting pep-
tides occurs in endosomal and/or lysosomal compartments
(24). Depending on the species origin of the cell, cell types,
or even on the maturation status in the case of dendritic
cells, accumulation of MHC class II molecules may occur
in different endocytic compartments (43, 51). In human
Epstein Barr virus–transformed B
 
 
 
(EBV-B) cells, HLA-
DR molecules accumulate in lysosomal compartments
named MHC class II compartments (MIICs; 49). In mu-
rine splenic lipopolysaccharide-activated B cells (18) as
well as in macrophages and human melanoma cells (30,
52), MHC class II is found all along the endocytic path-
way, from early endosomes to lysosomes. In contrast, A20
murine B lymphoma cells accumulate MHC class II mole-
cules in endosomal compartments, the class II vesicles (2,
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tor; CHS, Chediak-Higashi syndrome; DAMP, 
 
N
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3-amino-
 
N
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trafficking regulator; MHC, major histocompatibility complex; MIIC,
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4), whereas few class II molecules are found in conven-
tional endosomes and lysosomes. However, upon inhibi-
tion of Ii chain degradation, class II molecules redistribute
into lysosomal compartments (14).
Recent results from the laboratory of H. Geuze (50, 35)
showed that the distribution of MHC class II molecules in
EBV-B cells is not as restricted as initially envisioned. In-
deed, HLA-DR accumulates in two types of compart-
ments: (
 
a
 
) in endosomes containing multiple internal vesi-
cles that are reached by fluid phase markers after 20–30
min of internalization and contain some Ii chain (multive-
sicular late endosomes); and (
 
b
 
) in vesicles containing in-
ternal membranes organized in onion-like structures that
accumulate fluid phase markers only after 60 min and con-
tain no Ii chain (multilaminar lysosomal compartments).
Both types of compartments also contain Lamp1/2, CD63,
and HLA-DM.
The functional relevance of this heterogeneity of en-
docytic MHC class II–containing compartments is still un-
clear, and the precise role of multivesicular and multilami-
nar endosomes in MHC class II transport and Ii chain
degradation is not known. Moreover, it has recently been
shown that the antigenic peptides generated in endosomal
and lysosomal compartments might not be the same (30).
In addition, we have recently shown that antigen internal-
ization through different membrane receptors that may
deliver antigens to particular endocytic compartments re-
sults in presentation of different antigenic peptides (3).
To evaluate the role of this heterogeneity of endocytic
compartments in MHC class II transport and function, we
examined EBV-B cells of patients suffering from a rare
genetic immunodeficiency disease, the Chediak-Higashi
Syndrome (CHS), which affects the morphology and func-
tion of endocytic compartments. CHS results from muta-
tions in a gene encoding a large cytosolic protein called
lysosomal trafficking regulator (LYST), which displays
limited sequence homology to a regulatory subunit of the
yeast phosphatidyl-inositol-3 kinase (PI3K), VPS15 (9,
45). LYST also includes several WD40 and HEAT/ARM
domains, a domain of limited homology to stathmin, as
well as a unique domain that has been called BEACH (9,
8, 10, 45).
Despite having identified several subdomains in the
CHS protein, the precise function of the protein is not
known. We do know, however, that mutations in this gene
result in immunological disorders and susceptibility to
multiple childhood infections. The lysosomal compart-
ments in all cell types of CHS patients are enlarged,
reaching over 1 
 
m
 
m/vesicle (70). In hematopoietic cells,
including T lymphocytes, NK cells, and granulocytes, cyto-
toxicity is defective, most likely because of a defect in reg-
ulated secretion (61, 29, 6). In nonhematopoietic cells such
as melanocytes and kidney cells, enlarged lysosomal mor-
phology and defects in lysosomal enzyme secretion have
been reported (15). It is yet unclear whether the defect in
the secretory function of lysosomes in hematopoietic cells
is a consequence or a cause of the abnormal lysosomal
morphology. It is also possible that both phenotypes arise
from a unique upstream defect in the endocytic pathway.
Here we show that antigen presentation and MHC class
II intracellular transport are affected in EBV-B cells from
CHS patients. Surprisingly, only lysosomal multilaminar
MHC class II–containing compartments are enlarged,
while multivesicular late endosomes displayed normal size
and morphology. However, a severe reduction in the stain-
ing of multivesicular endosomes for MHC class II, Lamp
1/2, CD63, CD82, and 
 
b
 
-hexosaminidase was observed,
suggesting that transport of these markers from the TGN
and/or early endosomes into late endosomes is affected.
Missorting of resident lysosomal proteins to the plasma
membrane and early endosomes was also observed, as well
as a striking redistribution of the cation-dependent man-
nose-6-phosphate receptor (CD-MPR) into giant multi-
laminar lysosomes. In addition, we showed that LYST par-
tially colocalizes with microtubules, which have previously
been shown to play a critical role in transport from early to
late endosomes (19). Together, these results show severe
missorting of membrane proteins along the endocytic
pathway of CHS cells, and suggest that LYST may be di-
rectly involved in microtubule-dependent transport into
late endocytic compartments.
 
Materials and Methods
 
Antibodies and Cell Lines
 
All cell lines were maintained in RPMI 1640, 10% FCS (Sigma Chemical
Co., St. Louis, MO), 5 mM heat-inactivated glutamine, and 
 
b
 
-mercapto-
ethanol. Two CHS EBV-B cell lines were used: HLA DRB1* 0314 (JH)
and DRB1* 0113 (EA). JH cells were stably transfected with the 
 
b
 
-DR1
encoding cDNA to reconstitute the DR1 expression. Three human EBV
B cell lines—Hom-2 (homozygous DR1; 11), COX (homozygous DR3,
DRB1*0301), and PALA (homozygous DR3; 42)—were used as normal
controls in different sets of experiments. Anti-H3 specific T cells (TH1.7)
were Jurkat cells transfected with the 
 
a
 
 and 
 
b
 
 chains from a DR1/HA
306–319–specific T cell receptor (31).
The anti-MHC class II antibodies used in this study are: Tü36 (64),
L243 (63), Tal.1B5 (1), and DA6.147 (28). MHC class I molecules were
detected using HC10 (67). The antibodies against lysosomal markers were
Lamp1, a gift of Dr. Sven Carlsson (University of Umeå, Sweden), and
CD63 (37), obtained from B. Hoflack (Institut Pasteur Lille, France). The
CD-MPR antibody was a gift from Dr. A. Hille-Rehfeld (University of
Göttingen, Germany; 68), and the anti-HLA-DM antibody was from J.
Trowsdale (Imperial Cancer Research Fund, London, United Kingdom).
The anti-DNP antibody was from Molecular Probes, Inc. (Eugene, OR).
The anti LYST peptide-antiserum was raised against peptide 3426–3445
(KLNIEGELPAAVGLLVQFAF coupled to KLH). Specific antibodies
were isolated by affinity purification on the same peptide. The anti-
 
a
 
-tubu-
lin monoclonal antibody was purchased from Amersham Corp. (Arlington
Heights, IL). Secondary antibodies were: FITC-conjugated donkey anti–
mouse F(ab
 
9
 
)
 
2 
 
fragments, FITC-conjugated donkey anti–rabbit F(ab
 
9
 
)
 
2
 
fragments, and TR-conjugated donkey anti–mouse F(ab
 
9
 
)
 
2
 
 fragments
from Jackson Laboratories (Bar Harbor, ME).
 
FACS Analysis
 
Cells were washed twice in PBS and incubated for 20 min. with the pri-
mary antibodies and 20 min. with the secondary antibody. Acquisition and
analysis were performed on a FACscan (Becton Dickinson).
 
Intracellular Immunofluorescence and
Confocal Analysis
 
Paraformaldehyde fixation and immunofluorescent staining were per-
formed as previously described (13). In brief, the cells were fixed for 10
min at RT with 3% paraformaldehyde, and were washed with 5 mM PBS/
glycine to quench PFA excess. Permeabilization was performed with
0.05% saponin, 0.2% BSA in PBS for 30 min.
For anti-CHS and tubulin stainings, fibroblasts were fixed in ice-cold
methanol (
 
2
 
20
 
8
 
C) for 5 min, followed by a Saponin/BSA incubation as
described above. The cells were then analyzed by confocal microscopy
(TCS microscope; Leica AG, Heerbrugg, Switzerland). 
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Immunoelectron Microscopy
 
The B lymphoblastoid cells lines PALA and Hom-2, and the B-CHS cell
lines JH and EA, were fixed with 2% paraformaldehyde in 0.1 M phos-
phate buffer (PB), pH 7.4, for 1 h at room temperature. After blocking
with 50 mM glycine in PB, the cells were embedded in 7.5% gelatin. Small
gelatin blocks were infused in 2.3 M sucrose and frozen in liquid nitrogen
(57). Ultrathin cryosections were prepared with an ultracryomicrotome
(FCS; Leica AG) and a diamond knife (Drukker International, Cuijk, The
Netherlands), and were collected using a mixture of 2.3 M sucrose and
methylcellulose (vol/vol; 40). Ultrathin frozen/thawed sections were single
or double immunogold–labeled with different antibodies and protein A
gold conjugates (PAG 5, 10, 15; reference 57). Internalization of colloidal
gold-coupled bovine serum albumin (BSA-G) was performed by incubat-
ing 10
 
7
 
 cells for 10 min at 37
 
8
 
C with BSA-G in RPMI (OD
 
 5 
 
5). After
washing with ice-cold RPMI supplemented with 5% FCS, the endocytic
tracer was chased for 20, 50, or 120 min at 37
 
8
 
C. To analyze the acidity of
intracellular compartments, 10
 
7
 
 cells were washed with RPMI, and were
incubated with 
 
N
 
-3-(2,4-dinitroanilino)-3-amino-
 
N
 
-methyldipropylamine
(DAMP; Molecular Probes, Inc.) at a final concentration of 30 
 
m
 
g/ml for
30 min with ice-cold RPMI. After incubation with the endocytic tracer or
with DAMP, at the indicated times cells were fixed and processed as de-
scribed above.
 
Pulse Chase and Immunoprecipitations
 
Pulse chase, surface biotinylation, and immunoprecipitations were per-
formed as previously described (14). In brief, EBV-B cells were pulse-
labeled with 250 
 
m
 
Ci/ml [
 
35
 
S]Trans-Label™ (Amersham Corp.). The cells
were then chased in nonradioactive 5% RPMI1640 FCS, and were sur-
face-biotinylated with NHSS-biotin (Pierce Chemical Co., Rockford, IL)
at a final concentration of 2 mg/ml. The cells were lysed in 1 ml lysis buffer
(0.5% NP-40, 300 mM NaCl, 50 mM Tris pH 7.4, 20 mM NEM with an ad-
dition of protease inhibitors at a concentration of 10 
 
m
 
g/ml mix of leupep-
tin, chemostatin, aprotinin and pepstatin). MHC class II molecules were
immunoprecipitated using specific antibodies, and biotinylated class II
molecules were reprecipitated with streptavidin-agarose beads (Pierce
Chemical Co.). SDS-PAGE was carried out using 12% acrylamide gels (39).
Gels were fixed before drying, and were exposed for autoradiography.
 
Antigen Presentation Assay
 
UV-inactivated influenza virus and the hemagglutinin (HA) peptide 307–
318 were added to the plates at the indicated concentrations. 5 
 
3 
 
10
 
4
 
 TH
1.7 cells and 5 
 
3 
 
10
 
4
 
 EBV-B cells were added per well. After 24 h of incu-
bation at 37
 
8
 
C, IL-2 production was measured using the CTLL-2–depen-
dent T cell line (3). The B cells were pulsed with UV-inactivated influenza
virus or the M1 peptide for 3 or 24 h, and M1 presentation was assayed
with M1-specific cytotoxic T cell clone D9.1 in a 
 
51
 
Cr release assay (53, 54).
 
Mass Spectrometry
 
DR-associated peptides were analyzed by mass spectrometry as previ-
ously described (38). In brief, 5 
 
3 
 
10
 
8
 
 EBV-transformed B-LCL were used
for isolation in a micropreparative scale. About 5–10 
 
m
 
g of purified HLA-
DR molecules were extensively washed with aqua bidest in an ultrafree
ultrafiltration tube with a 30-kD cutoff (Millipore Corp., Bedford, MA).
Peptides were eluted by incubation in 0.1% trifluoro acetic acid for 0.5 h
at 37
 
8
 
C. After separating the protein by ultrafiltration, peptides were ly-
ophilized and prepared for mass spectrometry by dissolving them in 0.5 ml
1.4-diydroxybenzoic acid/acetonitrile (2:1). Spectra were recorded on a
Lasermat™ (Finnigan MAT GmbH, Bremen, Germany), and were col-
lected by averaging the ion signals from 20–50 individual laser shots.
 
Results
 
Antigen Presentation in B-EBV Cells from
CHS Patients
 
First, the ability of B-EBV cells from CHS patients to
present antigens in an MHC class II-restricted manner was
evaluated. We used T lymphocytes specific for two DR1-
restricted epitopes from the influenza virus: the H3 epitope,
corresponding to the 307–318 peptide from hemagglutinin
(HA), and the M1 epitope, corresponding to the 18–29
peptide from matrix protein. Control DR1
 
1
 
 B-EBV cells
(HOM-2) or B-EBV cells from two different patients (JH
and EA) were used as antigen-presenting cells (APCs).
These cells expressed similar levels of HLA-DR at their
surface, as assessed by FACscan analysis using L243 and
Tü36 mAbs (not shown). The JH cells did not express
HLA-DR1 endogenously, and were therefore transfected
with the cDNAs encoding the HLA-DR1 
 
b
 
 chain (JH-DR1).
Although difficult to evaluate directly, it is most likely that
the levels of HLA-DR1 in these cells are reduced as com-
pared with HOM-2 or EA cells.
In the case of the HA epitope, APCs were incubated
with complete antigen (i.e., UV-inactivated influenza vi-
rus) for different times (from 1 to 24 h). After glutaralde-
hyde fixation of the cells, anti-H3 TH 1.7 T cells were
added for 24 h, and IL-2 production was measured. As
shown in Fig. 1 
 
A
 
, the presentation of the H3 epitope was
delayed by 4–6 h in the two CHS EBV-B cells, as com-
pared with normal HOM-2 cells. All the cells presented
the H3 peptide with similar efficiencies and kinetics (not
shown).
To measure presentation of the M1 epitope, control
EBV-B cells (HOM-2) or CHS EBV-B cells (JH-DR1 and
EA) were cultured for either 3 or 24 h in the presence of
inactivated influenza virus, or of the corresponding 18–29
peptide from the M1 matrix protein. The cells were then
used as targets for cytotoxicity by a specific CD4
 
1
 
 DR1-
restricted cytotoxic T cell clone. As shown in Fig. 1 
 
B
 
, in-
cubation of antigen-presenting cells with the peptides for 3
or 24 h induced efficient antigen presentation and lysis of
the target cells. In contrast, when intact antigen was used,
presentation by the two CHS EBV-B cells was strongly
delayed, as compared with control HOM-2 cells (Fig. 1 
 
B
 
).
In the case of the EA cells, the overall efficiency of presen-
tation was reduced after both 3 and 24 h of incubation,
whereas in the case of the JH-DR1 cells, presentation was
delayed (presentation after 24 h of incubation was similar
to that found in HOM2 cells).
Therefore, the overall process of antigen presentation is
affected in CHS. This problem with antigen presentation
may result from different mechanisms, including defective
loading of the peptides onto MHC class II molecules and/
or an inefficient transport of the peptide/class II com-
plexes to the cell surface. We next tested these two possi-
bilities.
 
Peptide Loading Onto MHC Class II Molecules in CHS
 
The binding of certain peptides to MHC class II molecules
results in production of SDS-stable 
 
ab
 
-dimers (25). The
kinetics of SDS-stable MHC class II 
 
ab
 
-dimers were ana-
lyzed in control Hom-2 and CHS JH cells. After pulse-
chase labeling of control and CHS cells and surface biotin-
ylation, total and surface MHC class II molecules were se-
quentially precipitated with the monoclonal antibody
Tü36 and streptavidin beads, respectively. The precipi-
tates were then either incubated at room temperature or
boiled before analysis by SDS-PAGE in order to visualize
peptide-associated SDS-stable MHC class II molecules.
As shown in Fig. 2 
 
A
 
, SDS-stable dimers appeared after 
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2 h of chase in control cells as a band of 55 kD that was ab-
sent when the samples were boiled (
 
upper left
 
). In CHS
cells, SDS-stable forms were barely detected, even after 6 h
of chase (Fig. 2 
 
A
 
, 
 
lower left
 
), indicating that peptide load-
ing is strongly delayed in these cells. This delay was even
more clear when the surface MHC class II molecules were
analyzed (compare the upper and lower right panels).
However, SDS-stable dimers were detected in similar
amounts in CHS and control cells after 24 h of chase in
both total and surface MHC class II (Fig. 2 
 
B
 
). Therefore,
peptide loading is strongly delayed, but not absent in CHS
cells.
To evaluate if the peptides found on MHC class II mole-
cules in normal and CHS cells are qualitatively different
from each other, mass spectography of peptides eluted
from purified HLA-DR in CHS and control cells was per-
formed. As shown in Fig. 2 
 
C
 
, peptides eluted from both
CHS and control cells exhibited similar degrees of hetero-
geneity. Strikingly, however, the peptides eluted from
CHS cells were overall shorter by two amino acids than
were the peptides eluted from control cells. Likewise, only
the shorter forms of the class II–associated Ii chain pep-
tide (83–102 and 82–102) were found in CHS, whereas
normal cells also contained the 81–104 and 82–104 forms.
These results demonstrate that the peptides found associ-
ated to HLA-DR in CHS are overall shorter than those in
normal cells.
 
MHC Class II Transport to the Cell Surface in CHS
 
To investigate the kinetics of HLA-DR maturation and
transport to the cell surface, pulse-chase experiments were
performed on cells that were first surface-biotinylated. Af-
ter lysis, MHC class II molecules were precipitated with
the DA6.147 monoclonal antibody that recognizes all
MHC class II molecules, or with the L243 antibody that
recognizes only mature, Ii chain-free, 
 
ab
 
 dimers. The pro-
portion of mature HLA-DR molecules delivered to the
cell surface was evaluated by reprecipitating biotinylated
molecules with strepavidin-agarose.
Figure 1. (A) Presentation of the in-
fluenza hemagglutinin epitope H3 to
a class-II–restricted T cell hybridoma
was delayed in two CHS B cell lines
compared with control B cells. HOM-2
control cells or two EBV-B cell lines
from CHS patients (EA and JH-DR1)
were incubated with UV-inactivated
influenza virus for the indicated time
periods, and were fixed before incu-
bation with an anti-H3 T cell hybri-
doma. Antigen presentation was mea-
sured by IL-2 secretion. (B) MHC
class II–restricted presentation of the
influenza matrix epitope M1 was de-
layed in CHS B cells as compared
with controls cells. The cells were in-
cubated without (circles), or with ei-
ther the UV-inactivated influenza vi-
rus (squares) or with the M1 peptide
(triangles; 18–29) for 3 (open symbols) or 24 h (closed symbols). Control HOM2 cells and the CHS cell lines EA or JH-DR1 were as-
sayed for cytotoxicity by the DR1 restricted T cell line D1.9. The effector target ratios are indicated at the x axis. 
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As shown in Fig. 3 
 
A
 
 (
 
top
 
), the total amounts of newly
synthesized MHC class II and Ii chain, as detected with the
monoclonal antibody DA6.147, was similar in control and
CHS cells. This antibody efficiently precipitated 
 
ab
 
Ii com-
plexes, and thus allowed us to evaluate the rate of Ii degra-
dation. No significant difference was observed in Ii degra-
dation between control and CHS EBV-B cells. Using
direct precipitation of Ii chain with the mAb PIN1, no dif-
ference in the rates of degradation of Ii were observed
(not shown).
In contrast, appearance of mature L243-positive HLA-
DR molecules was delayed by 1 h, and the maximum lev-
els were slightly lower in JH CHS cells as compared with
control cells (Fig. 3 
 
A
 
, 
 
middle
 
). In contrast, a strong delay
was observed in the delivery of mature L243-positive
HLA-DR to the cell surface (Fig. 3 
 
A
 
, bottom). Quantifi-
cation of these results and calculation of the ratios of total-
to-surface molecules showed that the delay in the matura-
tion of HLA-DR molecules does not account for the delay
in cell surface appearance. Indeed, the rate of arrival of
mature HLA-DR to the plasma membrane, as measured
by the ratio of surface/total L243-positive HLA-DR mole-
cules at different times of chase, was decreased in CHS
cells (Fig. 3 
 
B
 
). In contrast, no difference in the rates of
cell surface transport of MHC class I molecules, which do
not transit through the endocytic pathway, was observed
between normal and CHS cells (Fig. 3 
 
C
 
). Therefore, at
least two different steps in MHC class II biogenesis are ef-
fected in CHS: (
 
a
 
) formation of mature, peptide loaded,
 
ab
 
 dimers; and (
 
b
 
) transport of mature MHC class II mol-
ecules to the plasma membrane.
 
MHC Class II–containing Compartments in CHS Cells
 
To analyze the basis of the functional disorders observed
in CHS EBV-B cells, we next analyzed the morphology of
Figure 2. (A) Delayed formation of SDS-stable dimers in CHS
B-cells. Immunoprecipitation of total (Tü36 mAb) and surface
(streptavidin-agarose) MHC class II molecules was performed af-
ter pulse-chase and cell surface biotinylation. The precipitates
were boiled or not before the samples were separated on SDS-
PAGE. (B) Similar amounts of SDS-stable dimers in CHS and
control cells were found after a 24-h chase. (C) Mass spectometry
profiles of DR-associated self-peptides from JH CHS cells and
control B-LCL COX cells. In CHS cells the mass range varied
between 1200 and 2600 D with a mode of 1700 D, whereas in con-
trol cells the masses ranged from 1500 to 2900 D with a mode
of 1900 D. Assuming an average amino acid mass of 115 D, pep-
tides from CHS cells are two amino acids shorter than those in
other B cells. Typical CLIP variants are marked by number:
CLIP (83–102; m/z 5 2221; peak 1); CLIP (82–102; m/z 5 2334;
peak 2); CLIP (82–104; m/z 5 2562; peak 3); and CLIP (81–104;
m/z 2675; peak 4; 62).  
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MHC class II–containing compartments. It has previously
been shown that all cells from CHS patients bear large cy-
toplasmic inclusions with characteristics of late endosomes
and lysosomes, which have been termed macrolysosomes.
In NK cells and cytotoxic T lymphocytes too, secretory
lysosomes are enlarged. To determine if MHC class II–
containing compartments in EBV-B lymphocytes from
CHS patients were enlarged, we first examined these cells
by immunoflurescence confocal microscopy using differ-
ent specific markers.
In normal EBV-B cells, MHC class II antibodies strongly
stained the cell surface, as well as numerous internal vesi-
cles in the perinuclear area and the cell periphery (Fig. 4,
 
C
 
 and 
 
D
 
). The internal vesicles were also labeled by anti-
HLA-DM and anti-Lamp1 antibodies, two markers of late
endosomes and lysosomes. In CHS cells, the morphology
of the internal vesicles labeled by these antibodies was
strikingly different (Fig. 4, 
 
A
 
 and 
 
B
 
). The vesicles were
larger and, although they costained for MHC class II and
either HLA-DM or Lamp1, the distribution of the mark-
ers was different within each of the macrovesicles: MHC
class II staining was homogenous throughout the compart-
ments, whereas HLA-DM and Lamp1 antibodies deco-
rated the periphery of the vesicles (Fig. 4, 
 
A
 
 and B).
Multivesicular and Multilaminar MHC
class II–containing Compartments in CHS
EBV-B Cells
In human EBV-B cell lines, the bulk of the intracellular
MHC class II molecules localize to late endosomal and ly-
sosomal compartments (49). A recent semiquantitative
analysis at the ultrastructural level of the localization of
MHC class II molecules in human and murine B cells indi-
cated that MHC class II distribution is broader than previ-
ously envisioned (35). The compartments where MHC
class II molecules were found can be distinguished on the
basis of their morphology, accessibility to endocytic trac-
ers (fluid phase markers or ligands internalized by recep-
tor mediated-endocytosis), specific markers, and acidity.
Low amounts of MHC class II molecules are detected in
tubulovesicular, transferrin receptor–positive early endo-
somes. MHC class II molecules are progressively enriched
in a set of later endocytic compartments that contain in
their lumen increasing numbers of internal 60–80 nm vesi-
cles (multivesicular compartments). Finally, one of the
major sites of accumulation of MHC class II molecules are
compartments displaying both internal vesicles and con-
centrically arranged membrane sheets (intermediate type),
or only membrane sheets (multilaminar compartments).
Figure 3. (A) Delayed maturation of MHC class II molecules.
CHS and control Hom-2 cells were labeled for 30 min with
[35S]cysteine-methionine and chased for the indicated time points.
Split parts of the lysates were immunoprecipitated with the mono-
clonal antibodies DA6.147 (nonconformational mAb) and L243
(which only binds to mature Ii chain–free MHC class II mole-
cules). Total amounts of class II molecules precipitated from the
two cell lines were similar (top). Generation of the L243 epitope
was delayed in the CHS cell line (top). Its surface appearance was
further delayed (bottom). (B) Densitometric quantification of the
autoradiographs in Fig. 3 A (top and bottom). Ratios of total to
surface L243 MHC class II molecules were calculated and plotted
against time. (C) No difference in rate of cell surface arrival of
MHC class I molecules (as detected by HC10 mAb) was observed
between control and CHS B-cells. Pulse-chase experiments and
immunoprecipitations of class I molecules were performed in JH
CHS B cells and control PALA cells.Faigle et al. Endosomal and Sorting Mechanisms in Chediak-Higashi Syndrome 1127
Examples of these compartments in human EBV-B cells
are shown in Figs. 5 A (multilaminar MIICs) and 7 C (mul-
tivesicular MIICs). Multivesicular and multilaminar MIICs
were similarly enriched in Lamp 1/2 (Figs. 5 A and 7 C),
HLA-DM, and CD63 (not shown).
In JH (see Fig. 9) and EA (not shown) cells, MHC class
II molecules were detected at the plasma membrane at
levels similar to those found in other B cell lines. Intracel-
lularly, most class II molecules were found in large (gener-
ally .1 mm diameter) multilaminar compartments (Fig. 5,
B and C). Occasionally, these compartments also con-
tained a small number of internal vesicles (arrows in Fig. 5
C). In addition to MHC class II molecules, all the protein
markers described to be enriched in multilaminar MIICs,
namely Lamp 1/2 (Fig. 5, B and C), HLA-DM, CD63, and
b-hexosaminidase (not shown), also accumulated in the gi-
ant CHS compartments. Macrolysosomes also accumu-
lated the weak base DAMP, showing that they acidified
normally (Fig. 6 B). Since giant compartments displaying
only internal vesicles were not found, we concluded that
only the multilaminar MIICs are enlarged in EBV-B lym-
phocytes from CHS patients.
In normal cells, multivesicular late endosomal compart-
ments have been proposed to play a critical role in MHC
class II transport and Ii chain degradation (50, 26, 58), and
to be involved in peptide loading onto MHC class II mole-
cules (69, 44). As shown in Fig. 7 C, multivesicular MIICs
in EBV-B cells contained MHC class II molecules and
Lamp 1/2 as well as CD63 and b-hexosaminidase (not
shown; see reference 36 for review). These vesicles were
also weakly stained by anti-Ii chain antibodies (50). Com-
partments displaying intralumenal vesicles were present in
the cytoplasm of CHS B cells. They were abundant, nor-
mally sized (mean diameter of 200 nm), and contained
normal numbers of internal vesicles in their lumen (Fig. 7
A). However, in contrast to normal EBV-B cells, very low
levels of MHC class II molecules and other protein mark-
ers (Lamp 1/2 as well as CD63 and b-hexosaminidase, not
shown) were detected in multivesicular compartments of
JH cells (Fig. 7 A). A semiquantitative analysis of the im-
munolabeling for MHC class II in multivesicular compart-
ments of normal EBV-B cells and JH CHS cells revealed
that only 8% of the compartments in CHS-B cells were la-
beled, and that the labeling never exceeded three gold par-
ticles. In normal EBV-B cells, 87% of the compartments
were labeled, and showed a mean of six gold particles per
compartment.
To further characterize multivesicular compartments
and the multilaminar macrolysosome in JH cells, we tested
the kinetics of accessibility to the endocytic tracer BSA-G.
Figure 4. MHC class II mole-
cules colocalize with Lamp1
and HLA-DM in macrolyso-
somes of JH CHS cells. JH
(A and B) and Pala (C and
D) cells were fixed, perme-
abilized, and stained with the
different antibodies. The
cells were incubated with ei-
ther an anti-Lamp1 (A and
C) or an anti-DM (B and D)
rabbit serum (Texas Red)
and L243 anti-MHC class II
mAb (A and D; FITC).The Journal of Cell Biology, Volume 141, 1998 1128
Cells were incubated for 10 min with the tracer, and were
chased for 20 or 150 min as described in Materials and
Methods. Multivesicular compartments of JH cells, de-
spite the fact that they do not label with anti–class II anti-
bodies, were reached by the tracer after 20 min of chase,
confirming their late endosomal/prelysosomal origin (Fig.
7 B). BSA-G was found in enlarged multilaminar compart-
ments only after 150 min of chase (not shown). Therefore,
BSA-G reached late endosomes and lysosomes with nor-
mal kinetics and efficiencies in CHS-B cells.
We also examined transport of membrane immunoglob-
ulins (mIg) to multivesicular endosomes after cross-link-
ing at the cell surface with rabbit anti–human IgG antibod-
ies. After a continuous internalization (30 min at 378C),
analysis of cryosections with anti-human IgG revealed that
mIgs were abundant in MHC class II/CD63 negative mul-
tivesicular compartments in JH cells (not shown). In con-
trast to the late endosomal/lysosomal compartment of
CHS B cells, early endosomes had normal morphology
and function. Tubulovesicular structures enriched in trans-
ferrin receptor were present beneath the plasma mem-
brane and in proximity to the Golgi complex (not shown).
In addition, uptake and recycling of radioactive Tf exhib-
ited similar kinetics in normal EBV-B and JH CHS B cells
(results not shown).
Taken together, these observations show that MHC
class II–containing multilaminar compartments are selec-
tively enlarged in B-CHS cells. The morphology of multi-
vesicular late endosomes is not altered, but expression of
resident membrane proteins is strongly reduced in these
compartments. Therefore, transport of endosomal/lysoso-
mal resident proteins in multivesicular late endosomes,
but not fluid phase markers or cross-linked mIg, is affected
in CHS EBV-B lymphocytes.
Missorting of Lysosomal Resident Membrane Proteins 
in CHS
Late endosomes receive membrane proteins mainly from
two different compartments: early endosomes and the TGN.
We reasoned that if transport of resident membrane pro-
teins into multivesicular late endosomes is defective in CHS,
an accumulation of molecules normally transported to late
endosomes and lysosomes should occur in the compart-
ments from where these proteins reach late endosomes,
i.e. early endosomes, plasma membrane, and/or TGN.
No evidence of accumulation of MHC class II or any
other lysosomal marker in the Golgi/TGN was observed by
electron or confocal microscopy (not shown). In contrast,
increased expression of Lamp1 and CD63 at the cell surface
was observed in JH (Fig. 8) and EA (not shown) by FACs-
can analysis. Similar results were obtained with HLA-DM
(not shown). In addition, Lamp1, CD63, and HLA-DM
were also found to accumulate in transferrin receptor–
containing early endosomes, and the plasma membrane by
Figure 5. Immunogold localization of MHC class II molecules
and Lamp1 in control Pala B cells and JH CHS EBV-B cells. Ul-
trathin cryosections were double immunogold labeled with anti-
MHC class II (PAG 10) and anti-lamp1 antibodies (PAG 15). (A)
In control B cells, MHC class II molecules were found in com-
partments showing concentrically arranged membrane sheets
(multilaminar MIICs), and had a mean diameter of 200 nm. (B)
At the same magnification, the multilaminar compartments con-
taining MHC class II molecules and Lamp1 in B cells from CHS
patients (JH) have a mean diameter of 1 mm. (C) An example of
an enlarged multilaminar compartment in JH cells double immu-
nogold–labeled with anti-class II (PAG 10) and anti-Lamp 1
(PAG 15) antibodies at a higher magnification. Small membrane
vesicles are eventually detected inbetween membrane sheets (ar-
rows in B and C). PM, plasma membrane. Bars, 200 nm.
Figure 6. Acidity of multilaminar MHC class II–containing com-
partments in control Pala B cells and CHS B cells. Cells were in-
cubated with DAMP for 30 min before fixation and processing
for cryosectioning. DAMP is visualized on ultrathin cryosections
with anti-DNP antibodies, and PAG 5. MHC class II molecules
were detected with an anti-class II antibody (PAG 10). The weak
base DAMP accumulates in multilaminar MIICs of control cells
(A) as well as in the enlarged MIIC in B cells from CHS patients
(JH; B). Bars, 200 nm.Faigle et al. Endosomal and Sorting Mechanisms in Chediak-Higashi Syndrome 1129
immunoelectron microscopy (not shown). These results
are consistent with a defective sorting of membrane mole-
cules from early endosomes and/or the TGN to late endo-
somes in CHS, causing accumulation of lysosomal resident
proteins in early endosomes and the plasma membrane.
Striking differences were also found in the case of CD-
MPR. In normal EBV-transformed B lymphocytes, MPR
accumulated in the TGN, and was barely detectable in
multivesicular compartments and totally absent from mul-
tilaminar compartments (27 and not shown). Surprisingly,
in CHS cells, the CD-MPR strongly accumulated in multi-
laminar macrolysosomes (Fig. 9 A), but was not detected
in multivesicular late endosomes, supporting an endoso-
mal sorting defect in CHS.
Fusion of MHC class II-containing Compartments with 
the Plasma Membrane
The results shown thus far may account for the delay in
MHC class II maturation and peptide loading observed in
CHS. However, our biochemical analysis showed that
transport of mature MHC class II to the cell surface is also
delayed in CHS. The pathways of MHC class II transport
to the cell surface are still unclear. Direct fusion of multi-
vesicular MHC class II–containing compartments and the
plasma membrane results in both delivery of the proteins
of the external membrane of the endosome to the cell sur-
face and secretion of the internal vesicles into the extracel-
lular medium. In addition, it has recently been proposed
that a defect in fusion of cytolytic granules with the plasma
membrane may occur in cytotoxic T lymphocytes. There-
fore, we next tested the possibility that fusion of multive-
sicular endosomes with the cell surface is deficient in CHS.
In normal EBV-transformed B cells, fusion of multive-
sicular MHC class II–containing compartments and the
cell surface were often observed (Fig. 9 C). The fusion
profiles contained previously internalized BSA gold, and
stained abundantly for MHC class II and different lysoso-
mal markers (including CD63 and CD82, not shown). In
CHS cells, fusion of multivesicular BSA-G–containing
compartments with the cell surface was also observed with
a frequency similar to that of normal cells (Fig. 9 B and not
shown). In contrast to normal cells, the vesicles secreted in
the extracellular medium in CHS cells did not label for
MHC class II (Fig. 9 B) or CD63 (not shown), consistent
with the observation that little MHC class II and CD63
was found in multivesicular late endosomes in these cells.
Occasionally, we also observed fusion of enlarged MHC
class II–positive multilaminar lysosomes with the plasma
membrane (not shown). In normal EBV-transformed B
lymphocytes, fusion of multilaminar compartments with
Figure 7. Multivesicular MIICs B cells from CHS patients (JH)
and control Pala B cells. (A) In JH cells, compartments displaying
intralumenal vesicles have normal morphology and size (mean di-
ameter of 200–300 nm). In these cells the majority of multivescu-
lar compartments do not label with anti-class II antibodies, while
strong labeling is observed in multilaminar compartments. (B)
MHC class II–negative multivesicular compartments contain
BSA-G after 30 min of internalization. (C) In control B cells, the
majority of the multivesicular compartments are double immu-
nogold–labeled with anti-class II (PAG 10) and anti-Lamp 1 anti-
bodies (PAG 15). Bars, 200 nm.
Figure 8. Cell surface accumulation of lysosomal markers in B
cells from CHS patients. FACS analysis of MHC class II mole-
cules (A and B), Lamp1 (C and D), and CD63 (E and F) in con-
trol PALA cells (A, C, and E) and JH CHS B cells (B, D, and F).The Journal of Cell Biology, Volume 141, 1998 1130
the plasma membrane was not observed. These results in-
dicate that direct fusion of endosomal multivesicular com-
partments with the plasma membrane is not deficient in
CHS EBV-transformed B cells.
Subcellular Distribution of LYST
The defect in transport of membrane proteins into multi-
vesicular late endosomes and the resulting missorting of
endosomal resident proteins that we have observed in
CHS may represent a direct or an indirect consequence of
the mutation in the Lyst gene. To analyze the intracellular
distribution of LYST, we raised a rabbit antiserum against
a peptide from the COOH-terminal region of LYST. Spe-
cific antibodies were affinity-purified. These antibodies
precipitated a 400-kD protein, consistent with the expected
molecular weight of LYST (not shown).
The intracellular distribution of LYST was analyzed in
HeLa cells by immunofluorescence and confocal micros-
copy. The affinity-purified antibody decorated small punc-
tated structures in the cytoplasm of HeLa cells (Fig. 10 A,
left). A subset (z50%) of these structures was aligned
along tubular processes that labeled for a-tubulin with
specific antibodies (Fig. 10 A, right). At higher magnifica-
tions in regions where microtubules were less concen-
trated, alignment of the LYST-positive structures along in-
dividual microtubules were observed (Fig. 10 A, bottom,
arrows). The staining with the anti-LYST antibodies was
abolished by the presence of 10 mM of the LYST peptide
(not shown). In addition, antibodies directed against a
peptide from the NH2 terminus of LYST also decorated
structures aligned along microtubules (F. Barrat and G.
De Saint-Basile, not shown), indicating that this staining is
not due to a cross-reaction of our antipeptide antibodies
with an unrelated protein.
LYST interaction with microtubules was confirmed by
treatment of the cells with nocodazole, which resulted in
microtubule dispersion (Fig. 10 B, top right), and of the
LYST-containing structures (Fig. 10 B, top left). Similar
results were found in EBV-B lymphocytes (not shown). In
addition, treatment of the cells with taxol, which stimu-
lates microtubule polymerization, resulted in a strong re-
distribution of both the anti-tubulin and anti-LYST stain-
ings (Fig. 10 B, bottom). These results indicate that the
LYST protein is found in punctated structures that inter-
act with microtubules.
Discussion
Although mutations in the lyst gene (in cells from CHS pa-
tients) results in dramatic and selective alterations of lyso-
somal morphology and function, the precise function of
LYST is still unclear. Importantly, other membrane com-
partments such as early endosomes, the ER, or the Golgi
apparatus, are not affected in CHS, suggesting that LYST
function is specifically related to late endosomes and lyso-
somes. The only endocytic function that was known to be
deficient in CHS hematopoietic cells thus far was cell-
mediated cytotoxicity. We now document that another im-
portant endocytic function in hematopoietic cells, i.e., anti-
gen presentation, is also affected. Our results on endosomal
sorting in late endosomes and the localization of LYST to
microtubule-associated structures, suggest a novel role for
the lyst gene product.
Endosomal Sorting Defect in CHS
The functional organization of the endocytic pathway in
EBV-B cells has been extensively analyzed (35, 49, 69, 18,
2). The first compartment where internalized membrane
proteins and fluid are delivered is a heterogenous popula-
tion of tubovesicular structures present in the cell periph-
ery, most often called early or sorting endosomes. Most of
the molecular sorting between the molecules that recycle
back to the plasma membrane and those that are delivered
to late endosomes and lysosomes occurs within early en-
dosomes. Late endosomes most likely form by fission of a
large portion of early endosomes (endocytic carrier vesi-
cles), which then mature into and/or fuse with multivesicu-
lar late endosomes. Multivesicular endosomes mature by
extensive exchange of membrane material with the TGN.
Mature multivesicular late endosomes eventually fuse
with preexisting multilaminar lysosomes, forming mixed
compartments that may then again mature to become mul-
tilaminar lysosomes.
It has been previously suggested that LYST may play a
role in endosomal sorting (70, 17). However, our results
first characterize a transport defect outside CHS macroly-
sosomes in late endosomal compartments. The absence of
resident endosomal proteins in late multivesicular endo-
somes, as well as mislocalization of several of these pro-
teins to either early endosomes/plasma membrane or lyso-
somes, suggests a defect in sorting of membrane proteins
Figure 9. (A) The CD-MPR accumulates in macrolysosomes in B
cells from CHS patients (JH cells). Immunogold localization of
MHC class II molecules (PAG 10) and CD-MPR (PAG 15) in
B-CHS cells. (B) Multivesicular compartments in JH cells fuse
with the cell surface. Previously internalized BSAG is reexternal-
ized together with internal vesicles. MHC class II molecules are
not detected in the externalized vesicles. (C) In control B cells
(PALA), the internal vesicles of multivesicular compartments are
strongly labeled with anti-class II antibodies. PM, plasma mem-
brane. Bars, 200 nm.Faigle et al. Endosomal and Sorting Mechanisms in Chediak-Higashi Syndrome 1131
in late endocytic compartments. We would like to propose
that the CHS defects in lysosomal shape and functions are
an indirect consequence of downstream sorting defects of
integral membrane proteins in late endosomes. Although
the molecules controlling lysosomal homeostasis (shape,
size, function, dynamics, etc.) are largely unknown, most
likely some of them are integral membrane proteins,
whose missorting would result in the morphological and
functional lysosomal defects characteristic of CHS.
This defect, however, does not affect delivery of internal-
ized fluid phase markers to late endosomes. Indeed, CHS
cells internalize and degrade a2-macroglobulin normally
(17), which is consistent with our findings with BSA-G, since
a2-macroglobulin dissociates from its receptor in early en-
dosomes and reaches late endosomes and lysosomes by
fluid phase. These results are not surprising, since fluid
phase marker delivery to late endosomes and lysosomes is
thought to occur by default in the absence of active sort-
ing. The observation that cross-linked mIg also reaches
multivesicular endosomes (not shown) indicates that trans-
port from early to late endosomes is not completely abol-
ished in CHS. One important difference between mIg and
the endosomal resident proteins that we have shown to be
absent from late endosomes in CHS is that only cross-
linked mIg must transit via early endosomes and not via the
TGN. Thus, the transport step defective in CHS might be
from TGN to late endosomes, and not from early to late
endosomes. However, mlg are only transported to lyso-
somes upon cross-linking, which activates protein tyrosine
kinases (PTKs). Sorting of mlg into late endosomes may
therefore require a different cytosolic sorting machinery
than other constitutive resident endosomal proteins (which
do not require cross-linking or activate PTKs). There-
fore, our results do not us allow to distinguish between an
early-to-late endosome or a TGN-to-late endosome defect
in CHS.
Accumulation of lysosomal markers in the macrolyso-
somes of CHS B cells, despite the apparent defect in trans-
Figure 10. The rabbit anti-LYST antibodies decorate structures
aligned along microtubules in fibroblasts (Hela cells). (A) Cells
were double-labeled with rabbit anti-LYST affinity-purified anti-
bodies (left) and monoclonal anti-a tubulin antibodies (right).
Higher magnification in lower panels shows alignment of the
LYST and microtubules (arrows). (B) Cells were treated with ei-
ther nocodazole (2 h at final concentrations of 10 mM; top) or
taxol (0.1 mM for 5 h; bottom) and stained for either LYST (left)
or microtubules (right). Nocodazole treatement disorganizes the
structures labeled by both antimicrotubule antibodies and LYST.
LYST is reorganized together with microtubules upon taxol
treatment.The Journal of Cell Biology, Volume 141, 1998 1132
port to late endosomes, may be accounted for in different
ways. It is possible that reduced levels of protein transport
through late endosomes are sufficient to allow accumula-
tion in lysosomes, which represent a terminal compart-
ment from where recycling back to the cell surface is slow
and inefficient. Alternatively, other transport pathways
from the TGN to lysosomes may also exist as described in
yeast, which may not involve late endosomes and could be
intact in CHS (55). The presence of the CD-MPR in mac-
rolysosomes may also be accounted for by missorting at
the TGN, and direct transport through a putative direct
TGN–lysosome pathway. The normal rates of Ii chain deg-
radation, too, may result from direct transport from the
TGN to lysosomes. However, it is also possible that the
sorting defects in CHS result in accumulation of cathep-
sins (maybe cathepsin S, which is thought to be involved in
Ii degradation in early endosomes (59) and Ii degradation
therein.
The Lyst Gene Product
The recent cloning of the lyst gene has revealed several in-
teresting features of LYST protein structure. The lyst gene
includes six exons, and encodes a large cytosolic protein.
Two major mRNA species of z6 and 13 kb were found by
Northern blot. The expected sizes of the Lyst gene prod-
ucts are z175 and 425 kD (8, 9). A functional domain of
345 amino acid residues called BEACH, highly conserved
between the human and murine putative proteins, is found
in the COOH-terminal region of LYST. The LYST pro-
tein also displays several HEAT and ARM repeats that
are present in various cytosolic proteins involved in mem-
brane transport (5). In the COOH-terminal region of
LYST, there is a cluster of seven WD40 motifs that is
involved in protein–protein interactions. This series of
HEAT/ARM and WD40 repeats in the COOH-terminal
domain of LYST is very similar to the structural organiza-
tion of VPS15, a regulator of the yeast PI3K (VPS 34; 66).
The human homologue of VPS15, a p150, has recently
been cloned and also presents homology to LYST COOH-
terminal domain (47). However, in contrast to VPS15 and
p150, LYST sequence does not suggest the presence of a
kinase domain.
The Vps15 mutant presents a defect in sorting to the
vacuole, causing secretion of vacuolar hydrolases. In yeast
and mammalian cells, PI3K is involved in endosomal
transport and sorting into late endosomes and lysosomes
(66, 21). This fact has been clearly demonstrated for the
PDGFR whose lysosomal transport is inhibited by muta-
tions that prevent PI3K activation (34). Furthermore,
wortmannin, a PI3K inhibitor, inhibits transport of mem-
brane proteins from endosomes to lysosomes (16). In addi-
tion, reminiscent of the phenotype of CHS cells, wortman-
nin caused accumulation of MPRs in swollen lysosomal
compartments in normal fibroblasts (20). The effect of
PI3K inhibitors on lysosomal transport in mammalian cells
and mutations in yeast, as well as the structural homology
of the lyst gene product and a regulatory subunit of the
PI3K, and the sorting defects in CHS cells suggest a func-
tional analogy in LYST and the PI3K membrane transport
involvement. The role of the PI3K in sorting endosomal
proteins is consistent with our findings and the hypothesis
that LYST is involved in protein sorting into late endo-
somes.
How is LYST Involved in Intracellular Transport?
A variety of different mechanisms have been proposed to
account for the CHS defect, including defects in lysosomal
fusion and fission, microtubules, and cytoskeleton. Al-
though a defect in the cytolytic granule fusion with the cell
surface was thought to occur in T-lymphocytes (6), the ev-
idence for it was indirect. Arguing against a defect in fu-
sion of endocytic compartments with the cell surface is the
observation that mast cells from beige mice do degranu-
late (32). In addition, Ca11-dependent secretion of lysoso-
mal enzymes occurs in fibroblasts (A. Rodriguez, personal
communication) from CHS patients. Our observation of
normal frequencies of fusion profiles of multivesicular late
endosomes and plasma membrane in CHS EBV-B cells
also supports the idea that the actual fusion of endocytic
compartments and the plasma membrane is not deficient
in CHS. This observation is also consistent with our pro-
posal that CHS cells present a membrane- sorting defect in
endosomes rather than a fusion defect, as previously envi-
sioned. The formation of enlarged macrolysosomes would
then represent an indirect consequence of endosomal mis-
sorting of membrane proteins involved in the control of ly-
sosomal morphology.
How then could the lyst gene product be involved in
membrane traffic? Our observations that antibodies to the
LYST protein decorate structures that partially codistrib-
ute with microtubules, and that are sensitive to nocoda-
zole, strongly suggest a microtubule-related function for
this protein. The presence of a domain homologous to
stathmin in the NH2-terminal domain of LYST could be
relevant from this point of view (45, 9). However, this ho-
mology is low, and its significance is still unclear. In addi-
tion, it was previously shown that CHS fibroblasts and
macrophages have normal microtubules (23), and that ly-
sosomal movement along microtubules is also normal in
CHS (48). However, a difference in microtubule growth
after stimulation was found in neutrophils from at least
certain CHS patients (56). Microtubules are directly in-
volved in different membrane transport steps, including
transport from early to late endosomes (19). Since we have
shown that transport into late endosomes is affected in
CHS, it is tempting to speculate that LYST is involved in
microtubule-dependent membrane traffic between early
and late endosomes. However, a microtubule-dependent
transport step in the TGN has also been described (19),
and a defect at this level could also account for the trans-
port defect in CHS cells.
Antigen Presentation and MHC Class II Transport
in CHS
Our results identify two steps in MHC class II intracellular
traffic that are affected in CHS: first, a delay in maturation
and peptide loading, and second, a delay in transport from
the endocytic pathway to the cell surface. The overall de-
lay in antigen presentation to helper T lymphocytes might
be related to this modification of MHC class II traffic. It is
also possible that other defects related to antigen internal-
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may contribute to the antigen presentation defect that we
describe here. However, antigen presentation was only de-
layed, and not abolished in CHS. Normal levels of SDS-
stable dimers were consistently detected at steady state.
For these reasons, it is unlikely that this defect in antigen
presentation participates significantly in the immunodefi-
ciency in CHS patients, which is more readily accounted
for by defects in cell-mediated cytotoxicity.
It was striking, however, to observe that the repertoire
of peptides bound to MHC class II are overall shorter by
one to two amino acids (the repertoire of peptides eluted
may not be compared, since JH cells are DR3/DR11 and
COX cells DR3/DR3). Given that MHC class II intracellu-
lar transport is significantly slower than that of normal
cells, peptides loaded onto MHC class II peptides might be
exposed to putative exopeptidases for longer periods of
time, which may result in more severe trimming of the
NH2-and/or COOH-terminal residues. The reduced levels
of MHC class II found in multivesicular late endosomes in
CHS, however, suggest that most peptide loading occurs in
enlarged macrolysosomes in CHS EBV-transformed B
cells. If this was indeed the case, the shorter mean length
of MHC class II-associated peptides in CHS cells may re-
flect a difference in the peptides generated in multivesicu-
lar late endosomes vs. multilaminar lysosomes. In any
case, this difference in the length of the loaded peptides in
CHS could influence the repertoire of T cell receptors se-
lected during thymic T cell maturation.
Whatever the molecular mechanism of the CHS defect
will turn out to be, it is striking and informative that de-
fects in late endosomal and lysosomal compartments in all
cells of the organism primarily affect important biological
functions in hematopoietic cells. The resulting immunode-
ficiency in CHS stresses the critical role of late endocytic
compartments in the systems of immune surveillance and
defense against infectious pathogens.
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